Sign Up For Future Updates
Breast Seromic™ Profiling AssayMonitoring proprietary antigens in breast cancer Breast cancer is the second most common cancer in women. Over 192,000 new cases will be diagnosed and approximately 41,000 deaths occur annually. There are primarily two forms of breast cancer: lobular and ductal carcinoma. Approximately 85% of all breast cancers are the ductal form. Treatment choice depends on whether the cancer has spread past the original cell type (invasive) or remained within the original cell type (in situ).
Three specific SEREX studies have been done in order to find genes associated with breast cancer. In the first study, Jäger et al. (1) analyzed one breast cancer library with autologous serum and pooled serum from 7 breast cancer patients. They found 89 clones derived for 30 genes and a new breast tumor suppressor gene, ING1. This may account for immune recognition in patients. In the second study, Jägeret al. (2) identified seven genes including a unique breast differentiation antigen NY-BR-1. This gene was found to be expressed only in breast and testis as well as 21 of 25 tumors examined .In the third study, Jäger et al. (3) also found the SCP-1 gene. A large scale SEREX on breast cancer was performed by Scanlan et al (4). After several rounds of SEREX, 40 antigens were found to react exclusively with sera from cancer patients. Genes identified in this work included NY_ESO-1, MAGE-3, MAGE-6, and p53. Combining SEREX Antigens with proprietary content Serametrix has now combined many of the important immunogenic antigens from our internal work with the SEREX work and other recent discoveries to produce our Seromic™ Profiling Assay for screening patient samples. Two more recent studies were done by Forti et al (5) and Minenkova et al (6) which discovered fibulin-1, thyroid hormone-binding protein, topoisomerase IIB, MUC3, Golgin p245 as potential genes of interest in breast cancer. The array composition was finalized using proteins identified from clinical trial data, disease and immunological expert opinions, comprehensive literature searches, as well as specific disease pathways.
For more information on the most current antigens, please contact us today by emailing info@serametrix.com.
References 1. Jäger D, Stockert E, Scanlan MJ, Güre AO, Jäger E, Knuth A, Old LJ, Chen YT, Cancer-testis antigens and ING1 tumor suppressor gene product are breast cancer antigens: characterization of tissue-specific ING1 transcripts and a homologue gene, Cancer Res. 1999;59(24):6197-204. 2. Jäger D, Stockert E, Güre AO, Scanlan MJ, Karbach J, Jäger E, Knuth A, Old LJ, Chen YT, Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library., Cancer Res. 2001;61(5):2055-61. 3. Jäger D, Unkelbach M, Frei C, Bert F, Scanlan MJ, Jäger E, Old LJ, Chen YT, Knuth A., Identification of tumor-restricted antigens NY-BR-1, SCP-1, and a new cancer/testis-like antigen NW-BR-3 by serological screening of a testicular library with breast cancer serum, Cancer Immunity, Vol. 2, p. 5. 4. Scanlan MJ, Gout I, Gordon CM, Williamson B, Stockert E, Gure AO, Jäger D, Chen YT, Mackay A, O'Hare MJ, Old LJ.,Humoral immunity to human breast cancer: antigen definition and quantitative analysis of mRNA expression, Cancer Immunity, Vol. 1, p. 4. 5. Forti S, Scanlan MJ, Invernizzi A, Castiglioni F, Pupa S, Agresti R, Fontanelli R, Morelli D, Old LJ, Pupa SM, Ménard S., Identification of breast cancer-restricted antigens by antibody screening of SKBR3 cDNA library using a preselected patient's serum., Breast Cancer Res Treat. 2002;73(3):245-56. 6. Minenkova O, Pucci A, Pavoni E, De Tomassi A, Fortugno P, Gargano N, Cianfriglia M, Barca S, De Placido S, Martignetti A, Felici F, Cortese R, Monaci P, Identification of tumor-associated antigens by screening phage-displayed human cDNA libraries with sera from tumor patients.,Int J Cancer. 2003;106(4):534-44.
|
|
